Subjects with Acute Leukemia or Myelodysplasic Syndrome, Myelofibrosis, or BPDCN for Chronic Myeloid Leukemia
Study Summary
This trial will test a new type of transplant that may be safer and more effective than the current standard.
- Chronic Myeloid Leukemia
- Myelodysplastic Syndrome
- Acute Leukemia
- Acute Lymphoblastic Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Acute Myeloid Leukemia
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Are applicants over the age of 45 being considered for participation in this research?
"The recruitment criteria for this trial require that prospective participants are at least 18 years of age and not yet 75."
Is enrollment still available for this research endeavor?
"Affirmative. The public-facing clinicaltrials.gov page states that this investigation is still open for recruitment of participants, with the initial post having been published on November 21st 2019 and last updated October 18th 2022. This trial requires 255 patients to be enrolled from 14 different sites."
What are the risk profiles associated with TregGraft (Orca-T) treatment?
"Considering the limited data on safety and efficacy, our team at Power has assigned TregGraft (Orca-T) a score of 1."
How many sites are involved in carrying out this experiment?
"14 sites are currently enrolling for this trial, including University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center in Miami, Weill Cornell Medicine - New York-Presbyterian Hospital in New York, and Winship Cancer Institute - Emory University in Atlanta. Other locations may also be available."
Do any particular demographics make for ideal study candidates in this trial?
"This clinical trial, which is recruiting 255 participants between 18-75 years of age that have myelodysplastic syndromes (MDS), has particular criteria for enrolment. These include having acute myeloid, lymphoid or mixed phenotype leukemia that isn't in CR/CRi (Ages 18-65); being categorized as DRI very high risk with the same condition(Ages 18-65); Myelofibrosis sufferers(18-65) and Blastic Plasmacytoid Dendritic Cell Neoplasms patients (18- 65). Furthermore, those aged 66 to 75 must possess"
How many participants have been selected to take part in this trial?
"To satisfy the study's requirements, 255 participants who meet the stated inclusion criteria must enroll. These individuals can seek enrollment in medical facilities such as University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center located in Florida, or Weill Cornell Medicine - New York-Presbyterian Hospital found in Georgia."